You are here: Industry Insights > Principia Biopharma

News List

Sanofi concludes acquisition of Principia Biopharma expresspharma
October 09, 2020
The Principia acquisition strengthens Sanofi’s core areas of autoimmune and allergic diseases.
Sanofi to acquire Principia Biopharma expresspharma
August 18, 2020
The deal adds to Sanofi’s R&D areas of autoimmune and allergic diseases.
Principia Biopharma lines up for $86M IPO fiercebiotech
August 22, 2018
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead asset into phase 3. The company's BTK inhibitor is currently in phase 2 trials for the autoimmune skin disease pemphigus and is also being developed for immune thrombo
Principia Biopharma lines up for $86M IPO fiercebiotech
August 21, 2018
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead asset into phase 3. The company's BTK inhibitor is currently in phase 2 trials for the autoimmune skin disease pemphigus and is also being developed for immune thrombo
Sanofi collaborates with Principia Biopharma to develop multiple sclerosis drug biospectrumasia
November 13, 2017
Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases
Bay Area's Principia Biopharma Scores $765M MS Licensing Deal With Drug Giant Sanofi biospace
November 10, 2017
SOUTH SAN FRANCISCO – A few months after striking a deal with AbbVie, Bay Area biotech Principia Biopharma has signed a deal worth up to $765 million with Sanofi for the development of a multiple sclerosis drug candidate.